Want to see JP:4151 full AI Analyst Report?
Kyowa Kirin Co (4151) Stock Price & Analysis
4151 Stock Chart & Stats
- Day’s Range
- JPY 2,401.50 - JPY 2,464.00
- 52-Week Range
- JPY 2,109.00 - JPY 2,912.00
- Previous Close
- JPY 2,401.50
- Volume
- 875.90K
- Average Volume (3M)
- 1.66M
- Market Cap
- JPY 1.29T
- Enterprise Value
- JPY 1.11T
- Total Cash (Recent Filing)
- JPY 265.08B
- Total Debt (Recent Filing)
- JPY 22.20B
- Price to Earnings (P/E)
- 15.9
- Beta
- 0.64
- Next Earnings
- Nov 02, 2026 (Est.)
- EPS Estimate
- 39.52
- Next Dividend Ex-Date
- Dec 29, 2026
- Dividend Yield
- 2.72%
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet
Very low leverage gives Kyowa Kirin substantial financial resilience and flexibility. The company can continue funding research, pipeline development, and commercialization without depending heavily on borrowing, helping it withstand business volatility while preserving strategic options.
Strong Profitability
High gross and operating margins indicate meaningful earnings power from Kyowa Kirin’s prescription-drug portfolio and biotechnology capabilities. Sustained profitability can support ongoing R&D, commercialization investment, and portfolio development while providing a buffer against cost pressure.
Healthy Cash Generation
Strong absolute operating and free cash flow demonstrate that the business is converting commercial activity into substantial internal funding. This supports investment in the pipeline, debt-light growth, shareholder distributions, and resilience through the next several quarters.
Bears Say
Moderating Revenue Growth
Slowing revenue expansion suggests that the current portfolio is not delivering the same acceleration seen during stronger periods. Persistently modest growth could limit operating leverage, reduce reinvestment capacity, and increase reliance on successful pipeline products or lifecycle initiatives.
Net Margin Compression
The decline in net margin indicates that profitability has not been fully sustained despite strong gross and operating margins. If the compression reflects mix, pricing, or cost pressure, it could reduce earnings conversion and constrain the company’s ability to compound shareholder returns.
Uneven Free Cash Flow Trend
Although current cash generation is substantial, declining and uneven free cash flow growth reduces visibility into future internal funding. Continued volatility could make investment pacing, distributions, and pipeline spending less predictable even with the company’s strong current liquidity position.
Kyowa Kirin Co News
4151 FAQ
What was Kyowa Kirin Co’s price range in the past 12 months?
What is Kyowa Kirin Co’s market cap?
When is Kyowa Kirin Co’s upcoming earnings report date?
How were Kyowa Kirin Co’s earnings last quarter?
Is Kyowa Kirin Co overvalued?
Does Kyowa Kirin Co pay dividends?
What is Kyowa Kirin Co’s EPS estimate?
How many shares outstanding does Kyowa Kirin Co have?
What happened to Kyowa Kirin Co’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Kyowa Kirin Co?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Kyowa Kirin Co
Operating globally, Kyowa Kirin Co., Ltd. is a pharmaceutical company focused on the discovery, development, manufacturing, and marketing of innovative medical therapies. The company's core areas of expertise span oncology, nephrology, central nervous system disorders, and immunology. Its extensive product portfolio includes established medications such as ABSTRAL, a sublingual fentanyl formulation for managing breakthrough pain in cancer patients; ALLELOCK, an antihistamine for various allergic conditions; and CONIEL, a calcium channel blocker prescribed for hypertension and angina. Kyowa Kirin also provides a range of advanced biological and specialized treatments. These encompass Crysvita, a recombinant human monoclonal IgG1 antibody targeting fibroblast growth factor 23, and blood-related therapies like ESPO (human erythropoietin), NESP (an erythropoiesis stimulating agent), and GRAN (a human colony-stimulating factor). Further products in its lineup address diverse medical needs: G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for opioid-induced constipation; Nouriast/Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. Other significant offerings are PecFent, a nasally administered spray; POTELIGEO, a humanized monoclonal antibody targeting CC chemokine receptor 4; REGPARA for secondary hyperparathyroidism; Romiplate/Nplate, a recombinant protein promoting platelet production; and SANCUSO for managing nausea and vomiting. Beyond its current offerings, Kyowa Kirin is actively involved in pipeline development, notably through a strategic collaboration with Amgen Inc. for the joint development and commercialization of KHK4083. This Phase 3-ready, fully human anti-OX40 monoclonal antibody is being developed to treat atopic dermatitis. Established in Tokyo, Japan, in 1949, the company changed its name from Kyowa Hakko Kirin Co., Ltd. to Kyowa Kirin Co., Ltd. in June 2019. It operates as a subsidiary of Kirin Holdings Company, Limited.
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Abdul Hafeez Mullick
- Employees
- 5,161
- Website
- www.kyowakirin.co.jp
- Address
- Otemachi Financial City Grand Cube, Tokyo, TY, 100-0004, JP
Kyowa Kirin Co (4151) Earnings & Revenues
4151 Company Deck
4151 Earnings Call
Earnings Call SentimentNeutral
The earnings call highlighted significant growth in North American and EMEA markets, particularly in strategic products like Crysvita and Poteligeo. However, this was offset by declines in overall revenue and interim profit due to restructuring costs and challenges in the Japanese market. While there were strong performances in certain segments and promising R&D developments, the financial declines and restructuring challenges resulted in a mixed sentiment.
View all JP:4151 earnings summaries4151 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 5 | 2 |
| Technical Analysis | 2 | 5 | 2 |
| Moving Averages | 12 | 0 | 0 |